Lexicon Pharmaceuticals, Inc. Forecast, price target & analysts
Lexicon Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Lexicon Pharmaceuticals, Inc. Classifications & Recommendation:
Lexicon Pharmaceuticals, Inc. Price Target
| Target Price | $2.95 |
| Price | $0.51 |
| Potential |
476.40%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Lexicon Pharmaceuticals, Inc. 2026 .
The average Lexicon Pharmaceuticals, Inc. target price is $2.95.
This is
476.40%
register free of charge
$6.00
1,072.33%
register free of charge
$0.80
56.31%
register free of charge
|
|
| A rating was issued by 6 analysts: 3 Analysts recommend Lexicon Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Lexicon Pharmaceuticals, Inc. stock has an average upside potential 2026 of
476.40%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 31.08 | 9.34 |
| 2,490.00% | 69.95% | |
| EBITDA Margin | -592.92% | -1,292.29% |
| 95.84% | 117.95% | |
| Net Margin | -732.75% | -1,432.03% |
| 96.96% | 95.43% |
5 Analysts have issued a sales forecast Lexicon Pharmaceuticals, Inc. 2025 . The average Lexicon Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Lexicon Pharmaceuticals, Inc. 2025 . The average Lexicon Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Lexicon Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Lexicon Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.63 | -0.37 |
| 21.25% | 41.27% | |
| P/E | negative | |
| EV/Sales | 5.69 |
5 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast for earnings per share. The average Lexicon Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Lexicon Pharmaceuticals, Inc....
Current Lexicon Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
